TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of patients who interrupted home hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improved depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oropharyngeal dysphagia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Assessment of Pain at Hour 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratio of RNFL / Full thickness retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician decision to increase glucocorticoids
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of HAC1 vaccine formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Reactogenicity of HAC1 vaccine formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of HAC1 vaccine formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Caregiver Well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depressive Symptoms in Caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assertivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Responsivity
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Expressive language (Word)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive language (Gestures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive Language (Word)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive Language (Sentences)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Sodium Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement rate between sample collection methods
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: State-Trait Anxiety Inventory-State Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of malaria attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Radial and Ulnar Arterial Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pulse rate trends
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse irregularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen saturation variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in physicians' treatment recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: lung aeration before and after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: re-intubation within 12, 36 or 72 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of SHR2554
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of SHR2554
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ventilated lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Acute Glucose-stimulated Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Insulin Sensitivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22, Overall and by Age Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Recurrent Ocular Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mississippi Scale for Combat-Related PTSD (M-PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients developing myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients developing stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of aphasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUClast of Lanraplenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Lanraplenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Lanraplenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting One or More Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Local and Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Discomfort between needle sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tear-film breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Schirmer test I without anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: corneal fluorescein staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in use of pain medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vascularization assessment by DCE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diabetic Retinopathy: Scale ETDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Urine albumin to creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sudomotor Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Syllables Stuttered (%SS) at entry to Stage II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Meningitis Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-16 and Anti-HPV-18 Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-diphteria and Anti-tetanus Concentrations ≥ 1.0 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Pertussis Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants with ASAS 20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluorescence loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell distribution width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Albumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants treated with WCD-treated ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Alive and Free From Advanced Respiratory Support Measures
Endpoint domain: Mortality/survival
Primary endpoint: severity of functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Resolution of respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory metaboreflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival after 6 months of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Total learning post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pack cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumor Response Rate (TRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abdominal compliance (Ca)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage concordance between MPS and standard microbiological technique results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight gain at the 7th day (g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the number of participants with feeding intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving 2, 3 or 4 points in the pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in subjective and objective sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Resilience Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thai Mental Health Indicator (TMHI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mechanical ventilation days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Distance walked in shuttle walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing cancer
Endpoint domain: Mortality/survival
Primary endpoint: Complication rate (device implantation)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days without catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean severity index of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AEC function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Diabetic Retinopathy Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: FACT-B summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body Satisfaction Scale (BSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infectious disease and chronic disease incidence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time in BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in noninvasive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tooth loss analysis (T fraction in DMFT teeth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Oral rehabilitation analysis (care index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Detectable Plasma Concentrations of Diacerein and Rhein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acne severity from Baseline to 365 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of acne relapse(s)/flare(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cardiff Acne Disability Index questionnaire (CADI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Signal Detection Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Default Network Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chronic rhinosinusitis (CRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prescription pickup within 24 hours of ED discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Binding of [11C]carfentanil in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of hyperglycaemia development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin consumption rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of hypoglycaemia development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in albumin transcapillary escape rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in albumin synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent or de Novo Arteriosclerotic Cardiovascular Disease (CVD)
Endpoint domain: Mortality/survival
Primary endpoint: Allergic reaction post DBPCFC
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of patients with sepsis and acute lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Dose to Primary Operator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the k-Value, a Measure of Delay Discounting of Alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to BIS-value <50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of skin wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in arginine-stimulated first phase insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Seated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of new neurological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measurement of CTP-543 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age adjusted height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age adjusted weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic encephalopathy-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Hemolysis frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glycaemic index of Manuka honey
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Polymerase Chain Reaction (PCR) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of functional digestive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EQ-5D-3L questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tampa scale for kinesiophobia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intravenous fluid requirement per percent total body surface area burn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mechanical ventilator free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication and infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Catheter-Related Blood Stream Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Long-term welfare dependency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Back strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change from Baseline in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of endovascular repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Telmisartan, Amlodipine, Rosuvastatin AUCτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telmisartan, Amlodipine, Rosuvastatin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life based on SNOT-22 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life based on Nasal and Sinus Symptoms Score questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of preoperative from postoperative CT endoscopic photo scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local control rate at 3-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: frequency of granulocytes PIG-A mutated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of long-term care residents receiving antipsychotics without psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of chronically infected children
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patient compliant with ePROM assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of clinical encounters using ePROM assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cervical volume removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Short term complications
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Reported Changes in New Bone Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Changes in Episodic Flare-Ups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Changes in Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pure Tone Audiometry PTA (dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 extrapolated to infinity [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Patient satisfaction OHIP 49 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The incidence of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The occurrence of lymphedema after follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Total beta power increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TTmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Incontinence Severity Index (ISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major adverse renal events
Endpoint domain: Adverse events/effects
Primary endpoint: Height for Age Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of the total hours medical device use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Achieving clinical stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COMRADE scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute bioavailability (AUC(inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of androgen receptors and tumor-related proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dosing accuracy (during treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease to follow the prescribed dosing schedule (during treatment)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning